Astellas Pharma Inc. has managed to win approval in one indication for its once-daily Astagraf XL (tacrolimus extended-release) for kidney transplant patients, several years after an initial filing that spanned three organs.
FDA approved the calcineurin inhibitor as a treatment to prevent organ rejection in kidney transplant patients on July 19. Astellas...